News | August 03, 2022
Jubilant Pharmova gets 6 observations from USFDA for its facility at Roorkee
he US FDA has issued six observations pursuant to the completion of the audit.
he US FDA has issued six observations pursuant to the completion of the audit.
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
Site Enhances New Modality CRDMO Platform Capacity for Customers
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Subscribe To Our Newsletter & Stay Updated
